Isomorphic Labs nabs $5B Series C
Isomorphic Labs raised a $5 billion Series C round to accelerate its AI-driven drug discovery pipeline. The company continues to advance its proprietary AlphaFold-powered design engine for oncology and immune-mediated diseases.
This massive $5B funding round signals a major market validation of AI-first computational engineering as the future of pharmaceutical R&D, positioning Isomorphic Labs to bridge the gap between digital simulation and clinical reality.
- –The scale of investment highlights how AI is fundamentally decoupling drug discovery from traditional, slow-moving laboratory iteration.
- –DeepMind's lineage, specifically the integration of AlphaFold 2 and 3, gives Isomorphic a massive technical moat in modeling complex biomolecular interactions.
- –With major partnerships already active, the company is now shifting focus toward accelerating its internal pipeline of high-value therapeutics toward clinical trials.
DISCOVERED
6h ago
2026-11-17
PUBLISHED
6h ago
2026-11-17
RELEVANCE
AUTHOR
demishassabis